Senthil Selvaraj1, Brian Claggett2, Sanjiv J Shah3, Inder Anand4, Jean L Rouleau5, Eileen O'Meara5, Akshay S Desai2, Eldrin F Lewis2, Bertram Pitt6, Nancy K Sweitzer7, James C Fang8, Marc A Pfeffer2, Scott D Solomon2. 1. Division of Cardiology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia (S.S.). 2. Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA (B.C., A.S.D., E.F.L., M.A.P., S.D.S.). 3. Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.). 4. Cardiovascular Division, VA Medical Center and University of Minnesota, Minneapolis (I.A). 5. Department of Medicine, Montreal Heart Institute, University of Montreal, Quebec, Canada (J.L.R., E.O.). 6. Department of Internal Medicine, University of Michigan, Ann Arbor (B.P.). 7. Sarver Heart Center, Division of Cardiology, University of Arizona College of Medicine, Tucson (N.K.S.). 8. Cardiology Division, University of Utah, Salt Lake City (J.C.F.).
Abstract
BACKGROUND:Albuminuria predicts adverse events in heart failure with preserved ejection fraction. No therapies to date have reduced albuminuria in heart failure with preserved ejection fraction. METHODS AND RESULTS: We analyzed 1175 participants from the Americas from the TOPCAT study (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) with urinary albumin:creatinine ratio (UACR) measurements at baseline. We examined the association of UACR with the primary outcome (cardiovascular death, aborted cardiac arrest, or heart failure hospitalization) and its individual components, all-cause mortality, and several safety end points using multivariable-adjusted Cox regression. We evaluated whether spironolactone reduced albuminuria at the 1-year visit in a subpopulation (N=744). Thirty-five percent had microalbuminuria, 13% had macroalbuminuria, and 80% were receivingangiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Increasing UACR was associated with male sex, higher systolic blood pressure, diabetes mellitus, and renal dysfunction. Macroalbuminuria (hazard ratio, 1.67; 95% CI, 1.22-2.28) and microalbuminuria (hazard ratio, 1.47; 95% CI, 1.15-1.86) were independently associated with the TOPCAT primary end point (compared with normoalbuminuria). Adjusting for placebo response, spironolactone reduced albuminuria by 39% in all participants at the 1-year visit compared with baseline (geometric mean ratio, 0.61; 95% CI, 0.49-0.77) and by 76% (geometric mean ratio, 0.24; 95% CI, 0.10-0.56) among those with macroalbuminuria. Reducing UACR by 50% was independently associated with a reduction in heart failure hospitalization (hazard ratio, 0.90; P=0.017) and all-cause mortality (hazard ratio, 0.91; P=0.019). The change in UACR was significantly associated with change in systolic blood pressure ( P=0.001). CONCLUSIONS: In TOPCAT, albuminuria was independently associated with worse cardiovascular outcomes. Spironolactone significantly reduced albuminuria compared with placebo. Reducing albuminuria was independently associated with improved outcomes. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00094302.
RCT Entities:
BACKGROUND:Albuminuria predicts adverse events in heart failure with preserved ejection fraction. No therapies to date have reduced albuminuria in heart failure with preserved ejection fraction. METHODS AND RESULTS: We analyzed 1175 participants from the Americas from the TOPCAT study (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) with urinary albumin:creatinine ratio (UACR) measurements at baseline. We examined the association of UACR with the primary outcome (cardiovascular death, aborted cardiac arrest, or heart failure hospitalization) and its individual components, all-cause mortality, and several safety end points using multivariable-adjusted Cox regression. We evaluated whether spironolactone reduced albuminuria at the 1-year visit in a subpopulation (N=744). Thirty-five percent had microalbuminuria, 13% had macroalbuminuria, and 80% were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Increasing UACR was associated with male sex, higher systolic blood pressure, diabetes mellitus, and renal dysfunction. Macroalbuminuria (hazard ratio, 1.67; 95% CI, 1.22-2.28) and microalbuminuria (hazard ratio, 1.47; 95% CI, 1.15-1.86) were independently associated with the TOPCAT primary end point (compared with normoalbuminuria). Adjusting for placebo response, spironolactone reduced albuminuria by 39% in all participants at the 1-year visit compared with baseline (geometric mean ratio, 0.61; 95% CI, 0.49-0.77) and by 76% (geometric mean ratio, 0.24; 95% CI, 0.10-0.56) among those with macroalbuminuria. Reducing UACR by 50% was independently associated with a reduction in heart failure hospitalization (hazard ratio, 0.90; P=0.017) and all-cause mortality (hazard ratio, 0.91; P=0.019). The change in UACR was significantly associated with change in systolic blood pressure ( P=0.001). CONCLUSIONS: In TOPCAT, albuminuria was independently associated with worse cardiovascular outcomes. Spironolactone significantly reduced albuminuria compared with placebo. Reducing albuminuria was independently associated with improved outcomes. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00094302.
Authors: Garabed Eknoyan; Thomas Hostetter; George L Bakris; Lee Hebert; Andrew S Levey; Hans-Henrik Parving; Michael W Steffes; Robert Toto Journal: Am J Kidney Dis Date: 2003-10 Impact factor: 8.860
Authors: Akshay S Desai; Eldrin F Lewis; Rebecca Li; Scott D Solomon; Susan F Assmann; Robin Boineau; Nadine Clausell; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Sonja McKinlay; Eileen O'Meara; Tamaz Shaburishvili; Bertram Pitt; Marc A Pfeffer Journal: Am Heart J Date: 2011-11-08 Impact factor: 4.749
Authors: Mauro Gori; Michele Senni; Deepak K Gupta; David M Charytan; Elisabeth Kraigher-Krainer; Burkert Pieske; Brian Claggett; Amil M Shah; Angela B S Santos; Michael R Zile; Adriaan A Voors; John J V McMurray; Milton Packer; Toni Bransford; Martin Lefkowitz; Scott D Solomon Journal: Eur Heart J Date: 2014-06-30 Impact factor: 29.983
Authors: Daniel H Katz; Senthil Selvaraj; Frank G Aguilar; Eva E Martinez; Lauren Beussink; Kwang-Youn A Kim; Jie Peng; Jin Sha; Marguerite R Irvin; John H Eckfeldt; Stephen T Turner; Barry I Freedman; Donna K Arnett; Sanjiv J Shah Journal: Circulation Date: 2013-09-27 Impact factor: 29.690
Authors: Stuart B Prenner; Anupam Kumar; Lei Zhao; Mary E Cvijic; Michael Basso; Thomas Spires; Zhuyin Li; Melissa Yarde; Priyanka Bhattacharya; Payman Zamani; Jeremy Mazurek; Zhaoqing Wang; Dietmar Seiffert; David A Gordon; Julio A Chirinos Journal: Am J Cardiol Date: 2019-11-19 Impact factor: 2.778
Authors: João Pedro Ferreira; Faiez Zannad; Javed Butler; Gerasimos Filippatos; Stuart J Pocock; Martina Brueckmann; Dominik Steubl; Elke Schueler; Stefan D Anker; Milton Packer Journal: JAMA Cardiol Date: 2022-09-21 Impact factor: 30.154
Authors: Rosalie A Scholtes; Michaël J B van Baar; Megan D Kok; Petter Bjornstad; David Z I Cherney; Jaap A Joles; Daniël H van Raalte Journal: Nephrology (Carlton) Date: 2021-01-04 Impact factor: 2.506
Authors: Edmund Ym Chung; Marinella Ruospo; Patrizia Natale; Davide Bolignano; Sankar D Navaneethan; Suetonia C Palmer; Giovanni Fm Strippoli Journal: Cochrane Database Syst Rev Date: 2020-10-27